The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Oct. 4 (UPI) --Eli Lilly on Wednesday announced Mike Mason, executive vice president and president of Lilly's diabetes and obesity division has retired. The company said in a statement that ...

Oct 4 (Reuters) - Eli Lilly and Co , opens new tab on Wednesday appointed a new chief for its diabetes and obesity unit in a string of leadership changes ahead of a key regulatory decision on the ...

Eli Lilly announced a series of changes to its leadership team Wednesday. As part of the shuffle, Mike Mason, Lilly’s EVP and president of Lilly Diabetes and Obesity, will retire at the end of the ...

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE:LLY) oral obesity pill, orforglipron. Roche Holdings AG (OTC ...

Eli Lilly's anti-obesity drug Zepbound (tirzepatide) receives approval in the US and recommended approval in the EU. The SELECT study data shows that semaglutide 2.4 mg reduces major adverse ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion ...

Eli Lilly on Wednesday announced Mike Mason, ... Eli Lilly names new head of diabetes and obesity division in leadership shakeup. Doug Cunningham. Wed, October 4, 2023 at 4:01 PM UTC.

CHGCY believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s LLY oral obesity pill, orforglipron. Roche Holdings AG RHHBY is a major shareholder of Chugai, a Japanese ...